Literature DB >> 12900362

Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis.

Oliver Stoeltzing1, Wenbiao Liu, Niels Reinmuth, Alexander Parikh, Syed A Ahmad, Young D Jung, Fan Fan, Lee M Ellis.   

Abstract

The fact that tumor growth and metastatic spread relies on angiogenesis has been widely proven and accepted. The understanding of cancer biology and metastasis formation has led to the development of new therapeutic approaches that target tumor biology. The survival and establishment of metastatic lesions depend on a shift in the normal balance of proangiogenic and antiangiogenic factors that favor angiogenesis. Colorectal cancer is one of the leading cancer deaths worldwide. Angiogenesis has been associated with colon cancer progression and metastatic spread, thereby significantly affecting patient survival. New experimental approaches that inhibit angiogenic processes have demonstrated promising antineoplastic effects on metastatic colorectal cancer and are partially being investigated in clinical trials. This review focuses on angiogenesis in colorectal cancer metastasis formation as a target for antiangiogenic therapy, describing the experience from experimental studies and current clinical trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900362     DOI: 10.1245/aso.2003.07.019

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

Review 1.  The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Semin Oncol       Date:  2006-12       Impact factor: 4.929

2.  The renin angiotensin system regulates Kupffer cells in colorectal liver metastases.

Authors:  Shu Wen Wen; Eleanor I Ager; Jaclyn Neo; Christopher Christophi
Journal:  Cancer Biol Ther       Date:  2013-06-17       Impact factor: 4.742

3.  Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -.

Authors:  Elena Tassi; Anton Wellstein
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

4.  Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.

Authors:  Xueming Wu; Eun-Kee Jeong; Lyska Emerson; John Hoffman; Dennis L Parker; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

5.  Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity.

Authors:  Praveen Rajendran; Manu Jaggi; Manoj K Singh; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2007-09-13       Impact factor: 3.850

6.  Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.

Authors:  Takamitsu Sasaki; Yasuhiko Kitadai; Toru Nakamura; Jang-Seong Kim; Rachel Z Tsan; Toshio Kuwai; Robert R Langley; Dominic Fan; Sun-Jin Kim; Isaiah J Fidler
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

7.  Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway.

Authors:  Shu-Chen Wei; Po-Nien Tsao; Meng-Tzu Weng; Zhifang Cao; Jau-Min Wong
Journal:  J Biomed Sci       Date:  2013-06-21       Impact factor: 8.410

8.  Suppression of metastasis of human pancreatic cancer cells to the liver by small interfering RNA-mediated targeting of the midkine gene.

Authors:  Li Yu; Yu Fan; Baoding Chen; Yue Hu; Yina Gao; DA Wei
Journal:  Oncol Lett       Date:  2013-09-12       Impact factor: 2.967

9.  Polysaccharide K suppresses angiogenesis in colon cancer cells.

Authors:  Yoshiki Satoh; Takanori Goi; Toshiyuki Nakazawa; Youhei Kimura; Yasuo Hirono; Kanji Katayama; Akio Yamaguchi
Journal:  Exp Ther Med       Date:  2012-07-04       Impact factor: 2.447

10.  The prometastatic microenvironment of the liver.

Authors:  Fernando Vidal-Vanaclocha
Journal:  Cancer Microenviron       Date:  2008-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.